A 52-year-old man from Delhi presents with a 3-month history of progressive jaundice, pale stools, and dark urine. On examination, he has hepatomegaly and a palpable epigastric mass. Abdominal ultrasound reveals a 4 cm hypoechoic lesion in the pancreatic head with dilated intrahepatic bile ducts. Serum CA 19-9 is markedly elevated at 320 U/mL (normal <37 U/mL), while CEA is normal. What is the most appropriate interpretation of the CA 19-9 result in this clinical context?

Explanation

## CA 19-9 in Pancreatic Cancer **Key Point:** CA 19-9 is a carbohydrate antigen (sialylated Lewis antigen) produced by pancreatic adenocarcinoma cells. While NOT diagnostic alone, it is highly sensitive (~80–85%) and moderately specific (~90%) in symptomatic patients with imaging evidence of pancreatic malignancy. ## Clinical Role of CA 19-9 | Aspect | Details | |--------|----------| | **Sensitivity** | 80–85% in pancreatic cancer | | **Specificity** | ~90% in symptomatic patients with imaging findings | | **Screening role** | NOT recommended (low specificity in asymptomatic populations) | | **Diagnostic role** | Supportive, NOT diagnostic alone; tissue biopsy is gold standard | | **Prognostic role** | Elevated levels correlate with advanced disease and poor prognosis | | **Monitoring role** | Useful for surveillance during treatment and detecting recurrence | **Clinical Pearl:** In this case, the combination of clinical presentation (jaundice, epigastric mass), imaging findings (pancreatic head lesion, biliary dilatation), and markedly elevated CA 19-9 strongly supports pancreatic adenocarcinoma. CA 19-9 adds diagnostic confidence but does NOT replace tissue confirmation. **High-Yield:** CA 19-9 is also elevated in benign conditions (pancreatitis, cirrhosis, cholangitis) and other malignancies (gastric, biliary, colorectal), so context is essential.